A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HPPH (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 16 Oct 2018 Biomarkers information updated
- 03 Dec 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 03 Dec 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.